Fecha de publicación: 27/01/2006 Fuente: WIPO "miel" Patent 522031

Described are soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4 per gram. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33 region and M97-G107 regions are mutated. The mutant molecules described may also include a second amino acid sequence that increases the solubility of the mutant molecule.